Microporous polysaccharide hemospheres for reducing pocket hematomas after cardiac device implantation in patients on antithrombotic therapy

IF 2.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Journal of Arrhythmia Pub Date : 2024-08-13 DOI:10.1002/joa3.13130
Yuko Matsui MD, Satoshi Higuchi PhD, Fumiaki Mori PhD, Kao Takehisa MD, Kensuke Kikuchi MD, Haruka Kikuchi MD, Kohei Hirobe MD, Ryozo Maeda MD, Kei Tsukamoto PhD, Takashi Saito MD, Morio Shoda PhD, Junichi Yamaguchi PhD
{"title":"Microporous polysaccharide hemospheres for reducing pocket hematomas after cardiac device implantation in patients on antithrombotic therapy","authors":"Yuko Matsui MD,&nbsp;Satoshi Higuchi PhD,&nbsp;Fumiaki Mori PhD,&nbsp;Kao Takehisa MD,&nbsp;Kensuke Kikuchi MD,&nbsp;Haruka Kikuchi MD,&nbsp;Kohei Hirobe MD,&nbsp;Ryozo Maeda MD,&nbsp;Kei Tsukamoto PhD,&nbsp;Takashi Saito MD,&nbsp;Morio Shoda PhD,&nbsp;Junichi Yamaguchi PhD","doi":"10.1002/joa3.13130","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Various surgical procedures have employed microporous polysaccharide hemosphere (MPH) hemostatic agents. However, data regarding their effectiveness in preventing pocket hematomas (PHs) during the implantation of cardiac implantable electronic devices (CIED) among the Asian population are limited. Therefore, this study aimed to investigate the potential benefits of using MPH hemostatic agents during CIED implantations as a preventive measure against post-procedural PHs.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a retrospective, single-center, observational study involving 255 consecutive Japanese patients who underwent CIED implantation between November 2017 and April 2021. We compared PH occurrences within 28 days after CIED implantation between patients who received MPH hemostatic agents (<i>n</i> = 145) and those who did not (<i>n</i> = 110).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>PH development was observed in nine (6.2%) patients who received MPH hemostatic agents and in 13 (11.8%) patients without MPH hemostatic (<i>p</i> = .111). Kaplan–Meier analysis of PH development revealed no significant difference between the two groups (log-rank <i>p</i> = .102). However, utilizing MPH hemostatic agents among patients taking antithrombotic drugs, including antiplatelet medications, direct oral anticoagulants, and warfarin, significantly reduced PH incidence (log-rank <i>p</i> = .03). The multivariate Cox proportional hazards model demonstrated that MPH hemostatic agent utilization independently correlated with a decreased PH risk (hazard ratio 0.22, 95% confidence interval 0.08–0.63, <i>p</i> = .004).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The findings of this study suggest that the incorporation of MPH hemostatic agents into standard practice may benefit to mitigate PH risk during CIED implantations in patients on antithrombotic therapy. This simple and practical measure may be valuable, especially in high-risk patients, such as those taking antithrombotic medications.</p>\n </section>\n </div>","PeriodicalId":15174,"journal":{"name":"Journal of Arrhythmia","volume":"40 5","pages":"1150-1157"},"PeriodicalIF":2.2000,"publicationDate":"2024-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/joa3.13130","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arrhythmia","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/joa3.13130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Various surgical procedures have employed microporous polysaccharide hemosphere (MPH) hemostatic agents. However, data regarding their effectiveness in preventing pocket hematomas (PHs) during the implantation of cardiac implantable electronic devices (CIED) among the Asian population are limited. Therefore, this study aimed to investigate the potential benefits of using MPH hemostatic agents during CIED implantations as a preventive measure against post-procedural PHs.

Methods

We conducted a retrospective, single-center, observational study involving 255 consecutive Japanese patients who underwent CIED implantation between November 2017 and April 2021. We compared PH occurrences within 28 days after CIED implantation between patients who received MPH hemostatic agents (n = 145) and those who did not (n = 110).

Results

PH development was observed in nine (6.2%) patients who received MPH hemostatic agents and in 13 (11.8%) patients without MPH hemostatic (p = .111). Kaplan–Meier analysis of PH development revealed no significant difference between the two groups (log-rank p = .102). However, utilizing MPH hemostatic agents among patients taking antithrombotic drugs, including antiplatelet medications, direct oral anticoagulants, and warfarin, significantly reduced PH incidence (log-rank p = .03). The multivariate Cox proportional hazards model demonstrated that MPH hemostatic agent utilization independently correlated with a decreased PH risk (hazard ratio 0.22, 95% confidence interval 0.08–0.63, p = .004).

Conclusions

The findings of this study suggest that the incorporation of MPH hemostatic agents into standard practice may benefit to mitigate PH risk during CIED implantations in patients on antithrombotic therapy. This simple and practical measure may be valuable, especially in high-risk patients, such as those taking antithrombotic medications.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
微孔多糖血球用于减少接受抗血栓治疗的患者植入心脏设备后的袋状血肿
背景各种外科手术都使用了微孔多糖血球(MPH)止血剂。然而,在亚洲人群中,有关微孔多糖止血剂在植入心脏植入式电子装置(CIED)过程中预防袋状血肿(PHs)有效性的数据十分有限。因此,本研究旨在探讨在植入 CIED 期间使用 MPH 止血剂作为预防术后血肿的措施的潜在益处。 方法 我们进行了一项回顾性、单中心、观察性研究,涉及 2017 年 11 月至 2021 年 4 月间接受 CIED 植入术的 255 名连续日本患者。我们比较了接受MPH止血剂治疗的患者(145人)和未接受MPH止血剂治疗的患者(110人)在CIED植入后28天内发生PH的情况。 结果 9 名(6.2%)接受 MPH 止血剂治疗的患者出现 PH,13 名(11.8%)未接受 MPH 止血剂治疗的患者出现 PH(P = .111)。PH发展的卡普兰-梅耶分析显示,两组之间没有明显差异(log-rank p = .102)。不过,服用抗血栓药物(包括抗血小板药物、直接口服抗凝剂和华法林)的患者使用 MPH 止血剂可显著降低 PH 的发生率(对数秩 p = .03)。多变量 Cox 比例危险模型显示,使用 MPH 止血药与 PH 风险的降低存在独立相关性(危险比为 0.22,95% 置信区间为 0.08-0.63,P = .004)。 结论 本研究结果表明,将 MPH 止血剂纳入标准实践可能有利于降低正在接受抗血栓治疗的患者在植入 CIED 期间的 PH 风险。这种简单实用的措施可能很有价值,尤其是对高风险患者,如服用抗血栓药物的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Arrhythmia
Journal of Arrhythmia CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
2.90
自引率
10.00%
发文量
127
审稿时长
45 weeks
期刊最新文献
Issue Information Dementia risk reduction between DOACs and VKAs in AF: A systematic review and meta-analysis Electro-anatomically confirmed sites of origin of ventricular tachycardia and premature ventricular contractions and occurrence of R wave in lead aVR: A proof of concept study The Japanese Catheter Ablation Registry (J-AB): Annual report in 2022 Slow left atrial conduction velocity in the anterior wall calculated by electroanatomic mapping predicts atrial fibrillation recurrence after catheter ablation—Systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1